NIAID leaders outline research agenda for universal, voluntary HIV testing and treatment

June 09, 2009

Could a global program of universal, voluntary, annual HIV testing and immediate treatment for those who test positive effectively extinguish the HIV pandemic? Is such a program feasible? In the June 10 issue of the Journal of the American Medical Association, top HIV/AIDS research leaders at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, set forth a research agenda to answer these and other provocative questions that may help shape the future of HIV prevention.

The inspiration for the research agenda outlined by NIAID Director Anthony S. Fauci, M.D., and the Director of NIAID's Division of AIDS, Carl Dieffenbach, Ph.D., is a mathematical modeling study published by scientists from the World Health Organization (WHO) in The Lancet in January 2009. The model by Granich et al. predicts that within 10 years of implementation, a program of universal, voluntary, annual HIV testing and immediate treatment for those who test positive could reduce HIV incidence from 20 new cases per 1,000 people per year--the current rate in places like South Africa--to less than 1 case per 1,000 per year. Further, the model predicts that this strategy, colloquially called "test and treat," could end the pandemic within 50 years. Some 33 million people globally are infected with HIV today.

"Given these conclusions, test and treat potentially could represent an important public health strategy for fighting HIV/AIDS," says Dr. Fauci. "However, the WHO model is based on numerous assumptions that need to be tested and also raises concerns about individual rights, cost effectiveness and other critical issues that require broad public debate."

To validate these assumptions and address these concerns, Drs. Dieffenbach and Fauci articulate a series of areas that define the test and treat research agenda for scientists in the field: Test and treat is one component of a three-part strategy that NIAID is examining to control the HIV/AIDS pandemic. NIAID-sponsored research under way on the second component involves testing whether antiretroviral drugs can prevent HIV infection in people at high risk for acquiring the virus, an approach known as pre-exposure prophylaxis, or PrEP. NIAID also is pursuing research to understand how HIV establishes and maintains latent pockets of infection; this information will be used in future studies to try to develop ways to control and eliminate the cells carrying latent virus, potentially curing people of HIV.

"NIAID is committed to investigating whether these and other experimental approaches to controlling HIV/AIDS work, because together, they have the potential to dramatically curtail the pandemic," says Dr. Dieffenbach.

NIAID and its many partners also are conducting research to refine and improve proven HIV prevention strategies such as education and behavior modification of people at risk for contracting or transmitting HIV, practical strategies for reducing HIV transmission among illicit injection drug users, antiretroviral treatment to prevent HIV transmission from mother to child, and medically supervised adult male circumcision. Research on still-experimental approaches to HIV prevention such as topical microbicides and vaccines continues as well.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at

The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit

References: CW Dieffenbach and AS Fauci. Universal voluntary testing and treatment for prevention of HIV transmission. Journal of the American Medical Association DOI: 10.1001/jama.301.22.2380 (2009).

RM Granich et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. The Lancet DOI: 10.1016/S0140-6736(08)61697-9 (2009).

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to